Katyal Nakul, Taqui Ather M, Tepper Deborah, Beary Jonathan M, Newey Christopher R
Department of Neurology, University of Missouri, Columbia, USA.
Neurology, Cleveland Clinic Ohio.
Cureus. 2018 Apr 12;10(4):e2467. doi: 10.7759/cureus.2467.
Herpes simplex-1 virus encephalitis (HSE) is the most commonly recognized cause of sporadic encephalitis in the United States. Historically HSE has been considered extremely detrimental given the associated relentless neurological deterioration secondary to cerebral edema and status epilepticus. With recent advances in antiviral therapeutics in past decades, the majority of complications can be managed effectively although the associated morbidity and mortality still remains high. The key modifiable factor determining recovery is the rapid initiation of antiviral therapy. We discuss the case of a 19-year-old female with HSE who received standard acyclovir therapy. Despite using recommended dosage and duration of acyclovir, her clinical condition worsened significantly and subsequently required multiple antiviral therapeutics and steroid therapy.
单纯疱疹病毒1型脑炎(HSE)是美国散发性脑炎最常见的已知病因。从历史上看,鉴于继发于脑水肿和癫痫持续状态的无情神经功能恶化,HSE一直被认为具有极大的危害性。尽管在过去几十年里抗病毒治疗有了新进展,大多数并发症可以得到有效控制,但相关的发病率和死亡率仍然很高。决定康复的关键可变因素是抗病毒治疗的快速启动。我们讨论了一名19岁患HSE女性接受标准阿昔洛韦治疗的病例。尽管使用了推荐剂量和疗程的阿昔洛韦,她的临床状况仍显著恶化,随后需要多种抗病毒治疗和类固醇治疗。